Discover how US drugmaker Alnylam is transforming from a rare disease specialist into a major therapeutic platform company and why the Edinburgh Worldwide team remain confident in the significant long-term potential. Capital at risk.
Edinburgh Worldwide: stock spotlight on Alnylam
More Articles
-
Scottish Mortgage on MercadoLibre: Building Latin America's Digital Future
Baillie Gifford
20 October 2025
-
Scottish Mortgage Digital Conference: Q&A Session
Baillie Gifford
17 October 2025
-
Scottish Mortgage: Blue Sky and Base Rates 10 Years On
Baillie Gifford
16 October 2025
-
Baillie Gifford: our best ideas in private growth
Baillie Gifford
15 October 2025
-
Baillie Gifford: our best ideas in China
Baillie Gifford
14 October 2025
Editor's Picks
Loading...